NCT00163215 - Growth Retardation In Children With Special Pathological Conditions Or Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Endocrine System Diseases

Interventions

DRUG

Somatropin

Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years

Trial Locations (18)

13385

Pfizer Investigational Site, Marseille

21000

Pfizer Investigational Site, Dijon

25030

Pfizer Investigational Site, Besançon

31026

Pfizer Investigational Site, Toulouse

33000

Pfizer Investigational Site, Bordeaux

33076

Pfizer Investigational Site, Bordeaux

34059

Pfizer Investigational Site, Montpellier

38043

Pfizer Investigational Site, Grenoble

54511

Pfizer Investigational Site, Vandœuvre-lès-Nancy

56100

Pfizer Investigational Site, Lorient

69322

Pfizer Investigational Site, Lyon

69677

Pfizer Investigational Site, Bron

74107

Pfizer Investigational Site, Annemasse

74374

Pfizer Investigational Site, Pringy

75015

Pfizer Investigational Site, Paris

75019

Pfizer Investigational Site, Paris

75571

Pfizer Investigational Site, Paris

75674 Cedex

Pfizer Investigational Site, Paris